A multi-center randomized 52 week treatment double-blind, triple-dummy parallel-group study to assess the efficacy and safety of QMF149 compared to mometasone furoate in patients with asthma
Phase of Trial: Phase III
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Indacaterol/mometasone (Primary) ; Mometasone; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors Novartis; Novartis Pharma A.G.
- 06 Mar 2018 Planned End Date changed from 1 Oct 2018 to 24 Jun 2019.
- 06 Mar 2018 Planned primary completion date changed from 1 Oct 2018 to 26 Nov 2018.
- 30 Sep 2016 Planned End Date changed from 1 Aug 2018 to 1 Oct 2018.